Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan

Yasushi Tsuji, Hideo Baba, Koji Takeda, Michiya Kobayashi, Eiji Oki, Masahiro Gotoh, Kazuhiro Yoshida, Mototsugu Shimokawa, Yoshihiro Kakeji, Keisuke Aiba

Research output: Contribution to journalArticle

4 Citations (Scopus)


Objectives: Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear. Methods: This multicenter, prospective, observational study analyzed the data of 190 colorectal cancer patients scheduled for moderately emetogenic chemotherapy (MEC). The patients recorded the incidence of CINV and severity of nausea by visual analogue scales daily for 7 days after receiving chemotherapy. Results: All 190 patients received MEC and 99% of patients received antiemetic therapy in compliance with guidelines. Acute CINV was well controlled. 13 (6.8%) patients suffered from acute nausea and 4 (2.1%) experienced acute vomiting, whereas the prevalence of delayed CINV was relatively high. Delayed nausea occurred in 71 (37.4%) patients and delayed vomiting in 24 (12.6%). History of motion sickness was a significant independent risk factor for delayed nausea (Odd ratio 3.89, 95% confidence interval 1.49–10.19, p = 0.0056). Conclusions: The compliance with CINV guidelines in colorectal cancer chemotherapy was quite high and led to good control of chemotherapy-induced vomiting in Japan. However, the incidence of delayed nausea remained high in patients receiving MEC.

Original languageEnglish
Pages (from-to)753-758
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Issue number8
Publication statusPublished - May 24 2017


All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this